Live Breaking News & Updates on Existing Data Support Regulatory

Submissions to Seek Approval in both ERT Naïve and ERT Switch Pompe Patients
Completion of Rolling Biologics License Application On-Track by end of 2Q21
PHILADELPHIA, May 03, 2021 (GLOBE NEWSWIRE) Amicus Therapeutics (NASDAQ:FOLD) today announced the completion of a successful Type B Pre-Biologics License Application (BLA) meeting with the U.S. Food and Drug Administration (FDA) for AT-GAA (cipaglucosidase alfa co-administered with miglustat), its investigational two-component therapy for the treatment of Pompe disease. Based on this formal pre-BLA meeting and the final written communication received from the FDA, Amicus intends to complete the rolling BLA submission for cipaglucosidase alfa and submit a New Drug Application for miglustat. ....

United States , Andrew Faughnan , Diana Moore , Johnf Crowley , Jeff Castelli , Amicus Therapeutics , European Medicines Agency , Drug Administration , Head Of Global Corporate Communications , Existing Data Support Regulatory , Seek Approval , Pompe Patients , Rolling Biologics License Application On Track , Typeb Pre Biologics License Application , New Drug Application , Chief Executive Officer , Chief Development Officer , Breakthrough Therapy Designation , Authorization Applications , Private Securities Litigation Reform Act , Pompe Disease , Annual Report , Global Corporate , ஒன்றுபட்டது மாநிலங்களில் , டயானா மூர் , ஜெஃப் காஸ்டெல்லி ,